Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2015 April;63(2) > Minerva Cardioangiologica 2015 April;63(2):135-49





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2015 April;63(2):135-49

language: English

Advanced therapeutic options in pulmonary hypertension: who, what and when?

Singh M. 1, Mishra A. 2, Rudzinski W. 1, Sporn D. 1, Kaluski E. 1, 3

1 Division of Cardiology, Guthrie Clinic, Robert Packer Hospital, Sayre, PA, USA;
2 Division of Internal Medicine, Guthrie Clinic, Robert Packer Hospital, Sayre, PA, USA;
3 Division of Cardiology, New Jersey Medical School, Newark, NJ, USA


Pulmonary hypertension (PH) is the common hemodynamic consequence of various pathophysiologic mechanisms. Since the publication of the most current American and European guidelines (2009) new agents were introduced into the clinical arena while data regarding former drugs has been substantiated. The therapeutic endeavor of evaluating new therapies for PH targets patients based on their PH type and symptom severity with the hope to demonstrate hemodynamic and functional benefits along with reduction in morbidity and mortality. Although patients’ outcomes (predominantly among type I and IV) have improved, the hemodynamic and symptomatic benefit is modest and not uniform. The purpose of this review is to objectively assess the benefits of the currently available dedicated agents. It is our hope that with early detection and careful individual titration of new combination therapy in expert hands, we will better serve a larger proportion of our PH patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail